The Clinical BioManufacturing Facility is the University of Oxford’s GMP (Good Manufacturing Practice) manufacturing facility.
The Clinical BioManufacturing Facility has over 20 years experience producing biological Investigational Medicinal Products (IMPs) according to the principles of GMP for early phase clinical trials. We hold a Manufacturer’s Authorisation for Investigational Medicinal Products (MIA (IMPs)) from the Medicines and Healthcare products Regulatory Agency (MHRA), which allows us to manufacture a variety of products including viral vector and recombinant protein vaccines and advanced therapy medicinal products (ATMPs) such as cell and gene therapy products. All IMPs are manufactured and released in accordance with the European Clinical Trials Directive (2004). The facility can also import IMPs from outside the EU for use in clinical trials within the European Union.
We aim to provide the link between academic research and clinical drug development, to allow all our collaborators to make rapid progress into clinical trials.
Our GMP manufacturing facility enables us to meet the special demands for phase I/II clinical trials of novel biotech products within the academic and commercial sectors and to deliver effective short term treatments to the clinic providing long term benefits to the patient.
Investment obtained by OxLEP helping to maintain vaccine development centre’s world-leading position
16 November 2023
Critical investment secured by OxLEP has enabled the refurbishment of key areas of a major biomanufacturing facility in Oxford, supporting its status as a global leader.
Call for applications to establish networks of epidemic and pandemic sciences research excellence across Africa
16 November 2023
PSI has joined forces with the Science for Africa Foundation and the Mastercard Foundation to launch a call for applications to establish innovative networks of research excellence in epidemic and pandemic sciences across Africa.
2 November 2023
Scientific advisors to the International Pandemic Preparedness Secretariat (IPPS) visited the University of Oxford’s vaccine laboratories as part of a two-day meeting of the global coalition.